Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis

被引：0
|
作者：
Masayuki Tanaka
Yasushi Ozeki
Fujio Matsuyama
Tatsunori Murata
Shinichi Imafuku
Taichi Nakamura
机构：
[1] Amgen K.K.,Inflammation and Immunology, General Medicine, Medical Affairs, Research and Development
[2] Crecon Medical Assessment Inc.,undefined
[3] Fukuoka University,undefined
来源：
Dermatology and Therapy | 2022年 / 12卷
关键词：
Apremilast; Biologic therapy; Japan medical cost; Psoriasis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：451 / 466
页数：15
相关论文
共 50 条
  • [1] Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis
    Tanaka, Masayuki
    Ozeki, Yasushi
    Matsuyama, Fujio
    Murata, Tatsunori
    Imafuku, Shinichi
    Nakamura, Taichi
    [J]. DERMATOLOGY AND THERAPY, 2022, 12 (02) : 451 - 466
  • [2] Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue
    Takamura, Saori
    Sugai, Sora
    Taguchi, Ryokichi
    Teraki, Yuichi
    [J]. JOURNAL OF DERMATOLOGY, 2020, 47 (03): : 290 - 294
  • [3] The first biologic therapy for psoriasis
    不详
    [J]. AMERICAN JOURNAL OF NURSING, 2003, 103 (05) : 64J - 64K
  • [4] Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis
    Metyas, Samy
    Messiah, Ramy
    Gettas, Tina
    Asfahani, Lisa
    Quismorio, Anne
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [5] Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis
    Metyas, Samy
    Tomassian, Christopher
    Messiah, Ramy
    Gettas, Tina
    Chen, Christina
    Quismorio, Anne
    [J]. CURRENT RHEUMATOLOGY REVIEWS, 2019, 15 (03) : 234 - 237
  • [6] COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain
    Queiro Silva, Ruben
    Armesto, Susana
    Gonzalez Vela, Carmen
    Naharro Fernandez, Cristina
    Angel Gonzalez-Gay, Miguel
    [J]. DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [7] TREATMENT PERSISTENCE IN PSORIASIS PATIENTS INITIATED ON APREMILAST, ORAL SYSTEMICS, OR BIOLOGIC THERAPIES
    Feldman, S. R.
    Kaura, S.
    Li, S.
    Tencer, T.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A805 - A805
  • [8] HEALTH CARE COSTS IN PSORIASIS PATIENTS NEWLY INITIATED ON APREMILAST OR BIOLOGIC THERAPIES
    Feldman, S.
    Kuznik, A.
    Clancy, Z.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A128 - A128
  • [9] Biologic therapy of psoriasis in haemodialysed patients
    Urbancek, S.
    Pecova, T.
    Vorcakova, K.
    Martinaskova, K.
    Bielikova, M.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 75 - 75
  • [10] SWITCH PATTERNS AND TOTAL COSTS IN BIOLOGIC-NAIVE PATIENTS INITIATING APREMILAST OR A BIOLOGIC FOR THE TREATMENT OF PSORIASIS
    Wu, J.
    Pelletier, C.
    Ung, B.
    Tian, M.
    Ni, Q.
    Curtis, J. R.
    [J]. VALUE IN HEALTH, 2018, 21 : S426 - S426
12345